At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Non-randomized Pilot Study to Determine the Safety and Efficacy of Two Weeks of Fixed-dose Glecaprevir and Pibrentasvir as Pre- and Post-exposure Prophylactic Therapy
In Brief
A Phase 4 clinical trial evaluating Glecaprevir/pibrentasvir for End Stage Renal Disease and Hepatitis C. Completed, enrolled 10 participants across 1 site.
Detailed Summary
In this study, individuals without hepatitis C infection who are on the kidney transplant waitlist will receive a kidney from a deceased donor with hepatitis C infection and will be treated for hepatitis C at the same time. Treatment will include glecaprevir 300 mg / pibrentasvir 120 mg (G-P) administered on-call to the operating room for the renal transplant procedure and continued for 2 weeks post-renal transplant.
Study Details
Timeline
Interventions
Glecaprevir/pibrentasvir 300mg/120mg once daily by mouth for 2 weeks post-transplant.